Results 191 to 200 of about 15,133,004 (307)

Psychological Distress Among US-Born and Non-US-Born Black or African American Adults in the US.

JAMA Netw Open
Elhabashy M, Adzrago D, Williams F.
europepmc   +1 more source

Prevention of Invasive Pneumococcal Disease Among Black or African American Children With and Without Sickle Cell Disease in the United States After Introduction of 13-Valent Pneumococcal Conjugate Vaccine, 2005 Through 2019. [PDF]

Pediatr Blood Cancer
Payne AB, Gierke R, Xing W, McGee L, Hulihan M, Adamkiewicz TV, Kobayashi M, Active Bacterial Core Surveillance Team.   +7 more
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

"That Was a State of Depression by Itself Dealing with Society": Atmospheric racism, mental health, and the Black and African American faith community. [PDF]

Am J Community Psychol
Desai MU, Guy K, Brown M, Thompson D, Manning B, Johnson S, Davidson L, Bellamy C.   +7 more
europepmc   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source

Re‐evaluating variability of circulating miR‐122 in healthy volunteers: Implications for biomarker qualification in drug‐induced liver injury

British Journal of Clinical Pharmacology, EarlyView.
Drug‐induced liver injury (DILI) remains a major challenge in clinical practice and drug development, and reliable biomarkers are still needed. MicroRNA‐122 (miR‐122) has shown promise, but reported inter‐individual variability in healthy populations has raised concerns about its clinical utility.
Irum Javid, Giusy Russomanno, Anthony Evans, Guruprasad P. Aithal, Shiva S. Forootan, Warren E. Glaab, Matthias Hackl, Joely Irlam, Kseniya Khamina‐Kotisch, Samantha Korver, Gerd A. Kullak‐Ublick, Sophia L. Samodelov, Christopher E. Goldring   +12 more
wiley   +1 more source

TWO WORLDS FAR APART: BLACK‐WHITE DIFFERENCES IN BELIEFS ABOUT WHY AFRICAN‐AMERICAN MEN ARE DISPROPORTIONATELY IMPRISONED*

, 2008
James D. Unnever
semanticscholar   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin   +11 more
wiley   +1 more source